| __timestamp | Bio-Techne Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 14400000 |
| Thursday, January 1, 2015 | 144969000 | 33800000 |
| Friday, January 1, 2016 | 162364000 | 35900000 |
| Sunday, January 1, 2017 | 188462000 | 1254000 |
| Monday, January 1, 2018 | 210850000 | 4889000 |
| Tuesday, January 1, 2019 | 240515000 | 7400000 |
| Wednesday, January 1, 2020 | 255497000 | 10100000 |
| Friday, January 1, 2021 | 298182000 | 14300000 |
| Saturday, January 1, 2022 | 349103000 | 23200000 |
| Sunday, January 1, 2023 | 366887000 | 39700000 |
| Monday, January 1, 2024 | 389335000 | 34000000 |
Cracking the code
In the dynamic world of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for two industry players: Neurocrine Biosciences, Inc. and Bio-Techne Corporation, from 2014 to 2023. Over this period, Bio-Techne consistently outpaced Neurocrine in cost of revenue, with a peak in 2023 reaching approximately 367 million, a 245% increase from 2014. In contrast, Neurocrine's cost of revenue showed a more modest growth, peaking at nearly 40 million in 2023, marking a significant rise from its 2014 figure. This disparity highlights Bio-Techne's expansive operational scale compared to Neurocrine. However, the absence of data for 2024 suggests potential shifts in strategy or reporting. As the biotech landscape evolves, understanding these financial dynamics offers valuable insights into each company's operational efficiency and strategic priorities.
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Bio-Techne Corporation
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Bio-Techne Corporation vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Bio-Techne Corporation vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bio-Techne Corporation vs Perrigo Company plc
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored